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L E T T E R TO TH E E D I T O R
Treatable traits in the European U‐BIOPRED adult asthma
cohorts
To the Editor,
Improvements in asthma outcomes have stalled over the past dec-
ade,1 which may be attributed to treating patients on the basis of a
generic diagnostic label. The taxonomy “Treatable Traits” was pro-
posed by Agusti et al (2016) as a precision medicine approach for
the diagnosis and management of chronic airway diseases that is
based on the identification of genetic, phenotypic and psychosocial
characteristics for which therapeutic interventions are known to
improve respiratory health.2 The Unbiased Biomarkers for the Pre-
diction of Respiratory Disease Outcomes (U‐BIOPRED) project was
set up to identify multidimensional phenotypes and endotypes in
severe asthma.3 Here, we aim to identify and quantify treatable
traits within the severe and mild/moderate U‐BIOPRED adult asthma
cohorts3 and across previously identified phenotypes.4 We hypothe-
size that treatable traits will be more common in severe asthma and
vary significantly across asthma phenotypes.
Data from the severe asthma and mild/moderate asthma cohorts
of the U‐BIOPRED project were included in this study. Full details of
the study population and methodology have been presented else-
where.3 Criteria for treatable traits were based on Agusti et al2 and
presented in Table 1. Chi‐squared tests were used to examine differ-
ences in the prevalence of each treatable trait between groups and
independent sample t tests used to determine differences in the total
number of traits between cohorts. No adjustment for multiple testing
was applied as the analyses were considered exploratory; as this may
inflate the type‐1 error rate, individual P values are presented for each
comparison. A post hoc power calculation shows our sample of 421
(severe smoking/ex‐smoking vs severe nonsmoking) and 399 (severe
nonsmoking vs mild/moderate) is sufficient to identify a difference in
treatable trait prevalence between cohorts with a medium effect size
(0.3) and a power close to 1.00. Data analysis was supported by IBM
SPSS Statistics for Windows, Version 24.0. Armonk, NY, USA, with
significance set at P < 0.05, unless otherwise stated.
1 | PREVALENCE OF TREATABLE TRAITS
Twenty‐three treatable traits were identified, including seven pul-
monary, 11 extra‐pulmonary and five behavioural/psychosocial treat-
able traits (Table 2). Seven out of the ten most prevalent traits in
severe asthma were classed as pulmonary treatable traits. The most
prevalent extra‐pulmonary traits were as follows: atopy, rhinosinusi-
tis, obesity, reflux and obstructive sleep apnoea. Poor adherence to
medication, anxiety and depression were the most common beha-
vioural/psychosocial treatable traits in severe asthma.
2 | DIFFERENCES IN TREATABLE TRAITS
ACROSS ASTHMA COHORTS
The severe smoking/ex‐smoking asthma cohort displayed on aver-
age one more treatable trait than the severe nonsmoking asthma
cohort (8 ± 3 vs 7 ± 2, P = 0.007). Differences in the prevalence of
individual traits, all higher in the smoking/ex‐smoking cohort, were
seen in bronchodilator reversibility, fixed airflow limitation
(P = 0.050), reflux, cardiovascular disease and psychiatric disease.
Only atopy was higher in prevalence in the nonsmoking cohort.
Nonsmoking individuals with severe asthma have more treatable
traits than nonsmoking individuals with mild/moderate asthma (7 ± 2 vs
5 ± 2, P < 0.001). Likewise, individual treatable traits were generally
more common in nonsmoking severe asthma compared to the mild/
moderate asthma cohort. Only in atopy and poor medication adherence
was the prevalence of the treatable trait significantly higher in mild/
moderate asthma. The prevalence of treatable traits across previously
identified clusters4 is presented and discussed on the Appendix S1.
3 | DISCUSSION
The identification of treatable traits facilitates a precision medicine
strategy for the management of airways disease, that is free from
the traditional diagnostic labels and based on the identification of
pulmonary, extra‐pulmonary and psychosocial characteristics, for
which there are evidence‐based therapeutic choices. This proposal
was recently supported by the Lancet commission “After asthma:
redefining airways disease”5 and was a favoured strategy to move
the field towards precision medicine at a research seminar, held at
the European Respiratory Society's annual meeting.6 Ours is the first
study to apply the concept to a large asthma cohort, and we have
identified a plethora of pulmonary, extra‐pulmonary and behavioural
/ psychosocial treatable traits. The prevalence of treatable traits,
both pulmonary and nonpulmonary, was generally higher in
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individuals with severe asthma compared to mild/moderate asthma.
We also identified a difference in the prevalence of pulmonary treat-
able traits across clinical clusters of patients. Approximately 5%‐10%
of asthmatics remain poorly controlled, despite being prescribed the
maximum dose of therapy.7 Our data suggest individuals with severe
asthma, who remain symptomatic despite receiving a high dose ICS,
display on average seven treatable traits, and therefore present mul-
tiple treatment opportunities beyond the traditional stepwise
approach.
Perhaps unsurprisingly, pulmonary traits accounted for seven of
the ten most prevalent treatable traits in our asthma cohorts and
were generally more common in severe asthma. Interestingly, how-
ever, we also observed an increased prevalence of extra‐pulmonary
and behavioural/psychosocial traits in severe asthma suggesting an
association with asthma severity, which may reflect the impact of liv-
ing with severe chronic respiratory conditions. Our data highlight that
multiple treatment opportunities exist beyond the pulmonary system,
and a holistic management strategy, such as the treatable trait
approach, may be beneficial to both physical and mental well‐being.
This is the first study to apply the concept of treatable traits to a
large asthma cohort. Several limitations are worthy of discussion; firstly,
we utilized the original paper on treatable traits,2 treatment guidelines
and clinical experience to determine the classification criteria for our
treatable traits. We acknowledge that our list of traits is not exhaustive
and that the selected criteria for some traits could be contentious.
Prospective studies would benefit from additional paraclinical investi-
gations to determine the prevalence of additional treatable traits, for
example ventilation heterogeneity and small airway disease. Finally, we
acknowledge that some traits may not be mutually exclusive and some
maybe modified by asthma treatment. Associations between traits
were not explored here but have been discussed elsewhere.8
In conclusion, the label‐free, precision medicine approach pro-
vided by the treatable traits construct allowed for the identification
of multiple treatment opportunities for patients with asthma, beyond
the traditional stepwise approach. We eagerly await the results of
prospective, longitudinal, clinical trials to determine whether this
translates to improved clinical outcomes for individuals with respira-
tory disease.
TABLE 1 Treatable traits and defining criteria
Treatable trait
category Treatable trait Defining criteria
Pulmonary Fixed airflow limitation Postbronchodilator FEV1/FVC < 0.7
Bronchodilator reversibility Postbronchodilator increase in FEV1 AND/OR FVC ≥12% AND ≥200 ml
Type 2 inflammation Sputum eosinophil count ≥ 2% AND/OR blood eosinophils ≥ 450 cells per ul
AND/OR FeNO > 50 ppb
Neutrophilic inflammation Sputum neutrophil count > 60%
Cough Asthma Quality of Life Questionnaire (AQLQ) Question 12 score ≤ 4 AND/OR
Sino‐Nasal Outcomes Test (SNOT‐20) Question score 4 ≥ 3
Exercise‐induced
respiratory symptoms
Medical history finding of “routine physical activity and/or physical exercise
as asthma trigger”
Bronchitis Medical history finding of “Current AND/OR chronic bronchitis”
Extra‐pulmonary Rhinosinusitis Medical history finding of “Allergic/Non‐allergic rhinitis active AND/OR
sinusitis active”
Nasal polyps Medical history finding of “Nasal polyps active”
Obese BMI > 30
Underweight BMI < 18.5
Obstructive sleep apnoea Epworth sleepiness scale score ≥ 11
Reflux Medical history finding of “Reflux active”
Vocal cord dysfunction Medical history finding of “Vocal Cord Dysfunction active”
Osteoporosis Medical history finding of “Osteoporosis active”
Cardiovascular disease Medical history finding of “Coronary disease active”
Eczema Medical history finding of “Eczema active”
Atopic Positive skin prick test AND/OR blood IgE result
Behavioural/psychosocial Smoking Medical history finding of “Current smoker”
Poor medication adherence Medication Adherence Rating Scale (MARS) mean score <4.5
Psychiatric disease Medical history finding of “Psychiatric disease active”
Depression Hospital Anxiety and Depression (HADS) depression domain score ≥ 11
Anxiety Hospital Anxiety and Depression (HADS) anxiety domain score ≥ 11
Treatable traits presented here are based on that of Agusti et al.2 BMI, body mass index; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity.
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